CORDIS
EU research results

CORDIS

English EN
New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases

New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases

Objective

Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people. The current therapies, including antibodies, show three main drawbacks: efficacy, tolerability and convenience. NEW DEAL solution will offer radical therapeutic progress for all IBD patients, thanks to the improved efficacy and increased safety of the specific JAK3 inhibition, which has been proven in clinics to be a target of great interest, the better tolerability of siRNA in term of immunogenicity and the good convenience with oral administration. To achieve this challenge, we will address three objectives: i) Specifically inhibit JAK 3 in a highly selective and safer manner by the mean of siRNA carefully designed and validated, ii) Deliver the siRNA therapeutic locally to the inflamed gut, by combining innovative nanostructured lipid carriers enabling their transport across the mucus, the intestinal barrier and the plasma membrane of the target cells, with polymeric capsules for protecting siRNA nanotherapeutics during their transit along the GI tract, thus allowing an oral administration, and iii) Promote the clinical translation and the future industrial transfer of this new clinical product, by addressing manufacturing, safety and efficacy evaluation at the late preclinical stage, to generate a Regulatory Submission Package and a Clinical Development Plan. The NEW DEAL project brings together clinical experts on IBD, leading scientists in nanomedicine, RNAi biology and immunology, innovative SMEs with a strong background in nanosafety, design of capsules and regulatory issues and an established pharma company with historic expertise on gastroenterology medicinal products. If successful, NEW DEAL will open new avenues for siRNA-based therapy in IBD with oral administration.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

Address

Rue Leblanc 25
75015 Paris 15

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 915 936,25

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

EUROPEAN RESEARCH SERVICES GMBH

Germany

EU Contribution

€ 233 337,50

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

Germany

EU Contribution

€ 384 965

NANOIMMUNOTECH SL

Spain

EU Contribution

€ 506 813,75

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 774 723,75

PRODIGEST

Belgium

EU Contribution

€ 463 343,75

SEPS PHARMA

Belgium

EU Contribution

€ 373 125

SPARKS & CO

France

EU Contribution

€ 43 886,94

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 475 258,75

LABORATOIRES MAYOLY SPINDLER

France

EU Contribution

€ 448 750

ALAN BOYD CONSULTANTS LIMITED

United Kingdom

EU Contribution

€ 188 750

SCIENSEED SL

Spain

EU Contribution

€ 190 288,06

Project information

Grant agreement ID: 720905

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.2.1.2.

  • Overall budget:

    € 5 999 178,75

  • EU contribution

    € 5 999 178,75

Coordinated by:

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France